Combination therapy with Bosentan and Sildenafil in PAH

تاریخ : ۱۳۹۳/۰۷/۰۳ / تعداد بازدید : ۲۴۰

ABSTRACT:

It has been proposed that targeted treatments should be combined for patients with idiopathic pulmonary arterial hypertension (IPAH) responding insufficiently to monotherapy.

This study followed the clinical course of nine patients with severe IPAH, in whom the endothelin receptor antagonist bosentan caused transient clinical improvement, eventually followed by a decline in exercise tolerance, who received adjunct treatment with the phospodiesterase-5-inhibitor sildenafil. Measurements included the 6-min walk distance (6MWD) and cardiopulmonary exercise testing (CPET).

The 6MWD at baseline was 346¡66 m and improved to 403¡80 m 3 months after introduction of bosentan treatment. However, this effect was not sustained and, after an interval of 11¡5 months, the walk distance had declined to 277¡80 m. At this point, sildenafil was added to bosentan. Three months later, the 6MWD had increased to 392¡61 m and the patients remained stable throughout the median follow-up of 9 months (range 6–12). Measurement of the maximum oxygen uptake during CPET confirmed these results. The combination of bosentan and sildenafil was well tolerated by all patients.

These preliminary data suggest that combining bosentan and sildenafil may be safe and effective in patients with idiopathic pulmonary arterial hypertension.

View full article here: Combination of bosentan and sildenafil in PAH

آخرین مقالات

ثبت مشخصات

نام

پست الکترونیک

کپچا

دیدگاه

Combination therapy with Bosentan and Sildenafil in PAH

Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis

دانستنی های مفید در خصوص حساسیت دارویی

دلایل و درمان سرگیجه

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosi

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis